Item 8.01. Other Events

As previously disclosed in a Form 8-K filed with the Commission on June 30, 2009, NovaDel Pharma Inc. (the "Company") entered into a Common Stock Purchase Agreement (the "Agreement") with Seaside 88, LP ("Seaside") whereby the Company agreed to issue and sell to Seaside, and Seaside agreed to purchase from the Company, 500,000 shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), once every two (2) weeks for twenty-six
(26) closings over a fifty-two (52) week period (the "Offering"). Pursuant to the terms of the Agreement, at the initial closing, the offering price of the Common Stock equaled 87% of the volume weighted average trading price of the Common Stock during the trading day immediately prior to the initial closing date. At each subsequent closing, on each 14th day thereafter, the offering price of the Company's Common Stock will equal 87% of the volume weighted average trading price of the Common Stock for the ten-day trading period immediately preceding each subsequent closing date. If, with respect to any subsequent closing, the volume weighted average trading price of the Company's Common Stock for the three trading days immediately prior to such closing is below $0.25 per share, then the particular subsequent closing will not occur and the aggregate number of Shares to be purchased shall be reduced by 500,000 shares of Common Stock.

Accordingly, on August 28, 2009, the Company had its fourth closing of the Offering pursuant to which Seaside purchased 500,000 shares of the Company's Common Stock at a price per share of $0.26 having an aggregate value of approximately $113,620, and, the Company received net proceeds of approximately $108,711, after deducting commissions and $1,500 in non-accountable expenses, pursuant to the terms of the Agreement.

---